Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bull 2X Shares

32.80
-0.3651-1.10%
Post-market: 32.72-0.0804-0.25%19:30 EDT
Volume:24.46K
Turnover:794.28K
Market Cap:18.04M
PE:- -
High:33.17
Open:33.17
Low:31.90
Close:33.17
52wk High:35.13
52wk Low:14.16
Shares:550.00K
Float Shares:550.00K
Volume Ratio:0.29
T/O Rate:4.45%
Dividend:3.17
Dividend Rate:9.65%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Stock (LLY) in Focus as Hedge Fund Titan Ken Griffin Quadruples Position

TIPRANKS
·
7 hours ago

Sector Update: Healthcare

MT Newswires Live
·
9 hours ago

Eli Lilly’s New Obesity Drug LY3549492 Moves Forward With Completed Phase 1 Trial

TIPRANKS
·
10 hours ago

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Simply Wall St.
·
Yesterday

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Yesterday

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Yesterday

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Yesterday

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Yesterday

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Yesterday

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?

Simply Wall St.
·
Aug 20

Amplitude Therapeutics: Lilly to GET Exclusive, Target-Specific Rights to Develop ,Commercialize Licensed Products Directed to Collaboration Targets

THOMSON REUTERS
·
Aug 20